BERTHELSEN SPENCER R
Known title: DirectorCIK: 0001181548
Associated companies
Transaction History
| IONS | ▲ Buy | Option Exercise | 5,220 | $0 | 7/15/2026 | View on chart |
| IONS | ▲ Buy | Option Exercise | 8,000 | $195K | 6/15/2026 | View on chart |
| IONS | ▼ Sell | Open Market | 8,000 | $588K | 6/15/2026 | View on chart |
| IONS | ▲ Buy | Option Exercise | 8,000 | $195K | 6/1/2026 | View on chart |
| IONS | ▼ Sell | Open Market | 8,000 | $605K | 6/1/2026 | View on chart |
| IONS | ▲ Buy | Option Exercise | 4,079 | $0 | 7/15/2025 | View on chart |
| IONS | ▲ Buy | Option Exercise | 4,677 | $0 | 7/15/2024 | View on chart |
| IONS | ▲ Buy | Option Exercise | 16,000 | $568K | 6/17/2024 | View on chart |
| IONS | ▼ Sell | Open Market | 16,000 | $645K | 6/17/2024 | View on chart |
| IONS | ▲ Buy | Option Exercise | 1,777 | $0 | 7/17/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,333 | $0 | 7/17/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 11,250 | $320K | 6/20/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,333 | $0 | 7/15/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 2,665 | $0 | 7/15/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 11,250 | $146K | 6/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cathie Wood adds to Ionis position amid RNA sector interest
Cathie Wood has increased her holdings in Ionis Pharmaceuticals as part of a broader bet on two stocks. This move highlights continued investor interest in RNA therapeutics, a sector currently drawing attention for its innovation potential. While the stock is trading near its 52-week low, the average analyst target remains significantly higher than the current price.
Cathie Wood adds to Ionis position amid RNA sector interest. Cathie Wood has increased her holdings in Ionis Pharmaceuticals as part of a broader bet on two stocks. This move highlights continued investor interest in RNA therapeutics, a sector currently drawing attention for its innovation potential. While the stock is trading near its 52-week low, the average analyst target remains significantly higher than the current price.